<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Insulin therapy - type 1 diabetes | Management | Insulin therapy in type 1 diabetes | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers general information on insulin therapy for people with type 1 diabetes."/><meta data-react-helmet="true" property="og:description" content="Covers general information on insulin therapy for people with type 1 diabetes."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Insulin therapy - type 1 diabetes | Management | Insulin therapy in type 1 diabetes | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Insulin therapy in type 1 diabetes</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Insulin therapy - type 1 diabetes</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/insulin-therapy-in-type-1-diabetes/","name":"Insulin therapy in type 1 diabetes"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/insulin-therapy-in-type-1-diabetes/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Insulin therapy - type 1 diabetes"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Insulin therapy in type 1 diabetes: </span><span>Scenario: Insulin therapy - type 1 diabetes</span></h1><p class="page-header__lead"><span>Last revised in July 2020</span></p></div><p class="visually-hidden">Covers general information on insulin therapy for people with type 1 diabetes.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Insulin therapy in type 1 diabetes chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Insulin therapy - type 1 diabetes"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Insulin therapy - type 1 diabetes</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#available-insulin-products">Available insulin products</a><ol aria-label="Sections within Available insulin products" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-885">Basis for recommendation</a></li></ol></li><li><a href="index.html#recommended-insulin-regimen">Recommended insulin regimen</a><ol aria-label="Sections within Recommended insulin regimen" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#adults">Adults</a></li><li class=""><a href="index.html#children-young-people">Children and young people</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-397">Basis for recommendation</a></li></ol></li><li><a href="index.html#accessories-for-insulin-therapy">Accessories for insulin therapy</a><ol aria-label="Sections within Accessories for insulin therapy" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-65b">Basis for recommendation</a></li></ol></li><li><a href="index.html#administration">Administration</a><ol aria-label="Sections within Administration" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ee5">Basis for recommendation</a></li></ol></li><li><a href="index.html#injection-technique">Injection technique</a><ol aria-label="Sections within Injection technique" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-b71">Basis for recommendation</a></li></ol></li><li><a href="index.html#injection-site">Injection site</a><ol aria-label="Sections within Injection site" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ecd">Basis for recommendation</a></li></ol></li><li><a href="index.html#storage-of-insulin">Storage of insulin</a><ol aria-label="Sections within Storage of insulin" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-239">Basis for recommendation</a></li></ol></li><li><a href="index.html#self-monitoring-of-blood-glucose">Self-monitoring of blood glucose</a><ol aria-label="Sections within Self-monitoring of blood glucose" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#target-levels-adults">Target levels - Adults</a></li><li class=""><a href="index.html#target-levels-children-young-people">Target levels - Children and young people</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-738">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-hypoglycaemia">Managing hypoglycaemia</a><ol aria-label="Sections within Managing hypoglycaemia" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#managing-an-episode-of-hypoglycaemia">Managing an episode of hypoglycaemia:</a></li><li class=""><a href="index.html#impaired-awareness-of-hypoglycaemia">Impaired awareness of hypoglycaemia</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-521">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-injection-site-problems">Managing injection site problems</a><ol aria-label="Sections within Managing injection site problems" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-d15">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-other-adverse-effects-of-insulin">Managing other adverse effects of insulin</a><ol aria-label="Sections within Managing other adverse effects of insulin" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-1ed">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-8f6">Basis for recommendation</a></li></ol></li><li><a href="index.html#safety-issues">Safety issues</a><ol aria-label="Sections within Safety issues" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-fc3">Basis for recommendation</a></li></ol></li><li><a href="index.html#lifestyle-cultural-issues">Lifestyle and cultural issues</a><ol aria-label="Sections within Lifestyle and cultural issues" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#lifestyle-advice">Lifestyle advice</a></li><li class=""><a href="index.html#driving">Driving</a></li><li class=""><a href="index.html#fasting-including-ramadan">Fasting, including Ramadan</a></li><li class=""><a href="index.html#shift-work">Shift work</a></li><li class=""><a href="index.html#holidays-travel">Holidays and travel</a></li><li class=""><a href="index.html#insurance">Insurance</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-575">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="insulin-therapy-type-1-diabetes" class="ChapterBody-module--wrapper--2HCfk "><h2 id="insulin-therapy-type-1-diabetes" class="visually-hidden">Scenario: Insulin therapy - type 1 diabetes</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 29958f4e-5204-482f-aac4-26806201d055 --><!-- begin field 7ed1e749-66ee-4544-bd57-acbc0155fb98 --><p>From age 12 months onwards.</p><!-- end field 7ed1e749-66ee-4544-bd57-acbc0155fb98 --><!-- end item 29958f4e-5204-482f-aac4-26806201d055 --></div><section aria-labelledby="available-insulin-products" class="ChapterBody-module--wrapper--2HCfk "><h3 id="available-insulin-products">What insulin products are available for people with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a95fc3aa-24cf-4bc4-b344-ae7cb60658e7 --><!-- begin field 53446822-7a67-49b8-9853-b12daf80b170 --><ul><li><strong>Three types of insulin are available in the UK:</strong><ul><li><strong>Human insulins </strong>are produced by recombinant DNA technology and have the same amino acid sequence as endogenous human insulin.</li><li><strong>Human insulin analogues </strong>are produced in the same way as human insulins but the insulin is modified to produce a specific desired kinetic characteristic (such as an extended duration of action or faster absorption and action).</li><li><strong>Animal insulins are</strong> extracted and purified from animal sources, either cows (bovine insulin) or pigs (porcine insulin).<ul><li>Although widely used in the past, animal insulins are no longer initiated in people with diabetes. However, they are still used in some people who cannot, or do not wish to, change to human insulins.</li><li>These insulins are not covered in this CKS topic.</li></ul></li></ul></li><li><strong>Insulins are broadly categorized according to their time-action profiles:</strong><ul><li><strong>Rapid- and short-acting insulins have a quick onset of action and a short duration of action. </strong>They are used to replicate the insulin normally produced by the body in response to glucose absorbed from a meal or sugary drink.<ul><li>Rapid-acting insulins have an onset of action of about 15 minutes and a duration of action is 2–5 hours. Examples include Humalog® (insulin lispro) and Novorapid<sup>®</sup> (insulin aspart).</li><li>Short-acting (regular or neutral) insulins have an onset of action of 30–60 minutes and a duration of action of up to 8 hours. Examples include Actrapid<sup>®</sup> and Humulin S<sup>®</sup>.</li></ul></li><li><strong>Intermediate- and long-acting insulins have a slow onset of action and a long duration of action. </strong>They mimic the effect of endogenous basal insulin (insulin that is secreted continuously throughout the day).<ul><li>Intermediate-acting (isophane) insulins have an onset of action of approximately 1–2 hours, maximal effects between 3–12 hours, and a duration of action of 11–24 hours. Examples include Humulin I<sup>®</sup>, Insuman Basal<sup>®</sup>, and Insulatard<sup>®</sup>.</li><li>Long-acting insulins have a duration of action of up to 24 hours; steady-state level achieved after 2–4 days to produce a constant level of insulin. Examples include Lantus<sup>®</sup> (insulin glargine), Levemir<sup>®</sup> (insulin detemir), and Tresiba<sup>®</sup> (insulin degludec).</li></ul></li></ul></li><li><strong>Several new insulin products have been launched in recent years:</strong><ul><li><strong>High strength insulins</strong> have concentrations greater than 100 units/mL and have been developed for people with large daily insulin requirements, to reduce the number and volume of injections. Examples are Tresiba<sup>®</sup> (200 units/mL), Humalog<sup>®</sup> (200 units/mL), and Toujeo<sup>®</sup> (300 units/mL).</li><li><strong>Insulin in fixed combination with liraglutide</strong> is a combination of a long-acting basal insulin and liraglutide (a glucagon-like peptide-1 [GLP-1] receptor agonist licensed for the treatment of type 2 diabetes). Xultophy<sup>®</sup> is a combination of insulin degludec 100 units/mL with liraglutide 3.6 mg/mL in a prefilled pen. </li><li><strong>Biosimilar insulin </strong>is a biological copy of an original insulin. Abasaglar<sup>®</sup> is a biosimilar insulin product based on insulin glargine 100 units/mL (Lantus<sup>®</sup>) and is licensed for the treatment of diabetes in adults, adolescents, and children aged 2 years and older. </li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) has issued <a href="https://www.gov.uk/drug-safety-update/high-strength-fixed-combination-and-biosimilar-insulin-products-minimising-the-risk-of-medication-error" target="_top" data-hyperlink-id="0e57c298-1bd9-44a8-bece-abe8012ecc7d">advice for healthcare professionals</a> to minimize the risk of medication error with these products.</li></ul></li></ul><!-- end field 53446822-7a67-49b8-9853-b12daf80b170 --><!-- end item a95fc3aa-24cf-4bc4-b344-ae7cb60658e7 --></div><section aria-labelledby="basis-for-recommendation-885" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-885">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 885f14c5-cc46-4c86-8f52-0f01b1b94ca2 --><!-- begin field f6cfd5e6-1016-4522-9ccd-0e1ec2fa8ae8 --><p>This information is taken from the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016b</a>], from information on the Diabetes UK website (<a href="http://www.diabetes.org.uk/" data-hyperlink-id="ea820372-aec7-46df-aceb-a931009aa7bf">www.diabetes.org.uk</a>) and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field f6cfd5e6-1016-4522-9ccd-0e1ec2fa8ae8 --><!-- end item 885f14c5-cc46-4c86-8f52-0f01b1b94ca2 --></div></section></section><section aria-labelledby="recommended-insulin-regimen" class="ChapterBody-module--wrapper--2HCfk "><h3 id="recommended-insulin-regimen">What is the recommended insulin regimen for people with type 1 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 58ad4834-dcc4-4ed3-aff1-422d39c45a4a --><!-- begin field f3e39196-64a2-4930-8420-e14a6297ddf5 --><p><strong>Insuli</strong><strong>n therapy for people with type 1 diabetes should only be initiated and managed by healthcare professionals with the relevant expertise and training.</strong> </p><ul><li><strong>There are different types of insulin regimens:</strong><ul><li><strong>Multiple daily injection basal-bolus insulin regimens</strong> — the person has injections of <a class="topic-reference internal-reference" href="index.html#available-insulin-products">short-acting</a> insulin or <a class="topic-reference internal-reference" href="index.html#available-insulin-products">rapid-acting</a> insulin analogue before meals, together with one or more separate daily injections of <a class="topic-reference internal-reference" href="index.html#available-insulin-products">intermediate-acting</a> insulin or <a class="topic-reference internal-reference" href="index.html#available-insulin-products">long-acting</a> insulin analogue to cover the basal requirement. This regimen offers greater flexibility for blood glucose control.</li><li><strong>Mixed (biphasic) regimen</strong> — the person has one, two, or three insulin injections per day of <a class="topic-reference internal-reference" href="index.html#available-insulin-products">short-acting</a> insulin or <a class="topic-reference internal-reference" href="index.html#available-insulin-products">rapid-acting</a> insulin analogue mixed with <a class="topic-reference internal-reference" href="index.html#available-insulin-products">intermediate-acting</a> insulin. The insulin preparations may be mixed by the person at the time of injection, or a premixed product can be used. </li><li><strong>Continuous subcutaneous insulin infusion (insulin pump) therapy</strong> — this is a programmable pump and insulin storage reservoir that gives a regular or continuous amount of insulin (usually in the form of a <a class="topic-reference internal-reference" href="index.html#available-insulin-products">rapid-acting</a> insulin analogue or <a class="topic-reference internal-reference" href="index.html#available-insulin-products">short-acting</a> insulin) by a subcutaneous needle or cannula.<ul><li>Insulin pump therapy dispenses with the need for an <a class="topic-reference internal-reference" href="index.html#available-insulin-products">intermediate-acting</a> or <a class="topic-reference internal-reference" href="index.html#available-insulin-products">long-acting</a> insulin to provide basal cover.</li><li>The pump can be programmed to deliver different basal rates of insulin at different times of the day and night, with higher infusion rates triggered by the push of a button at mealtimes.</li><li>The insulin requirement can be matched more closely to the person's basal requirement, pre-prandial glucose levels, carbohydrate intake, and physical activity.</li><li>Insulin pump therapy is considerably more expensive than insulin injections and should only be initiated by a trained specialist team, which should normally comprise of a physician with a specialist interest in insulin pump therapy, a diabetes specialist nurse, and a dietician.</li></ul></li></ul></li><li><strong>See the sections on <a class="topic-reference internal-reference" href="index.html#adults">adults</a> and <a class="topic-reference internal-reference" href="index.html#children-young-people">children and young people</a> for the recommended regimens for adults and children with type 1 diabetes.</strong></li></ul><!-- end field f3e39196-64a2-4930-8420-e14a6297ddf5 --><!-- end item 58ad4834-dcc4-4ed3-aff1-422d39c45a4a --></div><section aria-labelledby="adults" class="ChapterBody-module--wrapper--2HCfk "><h4 id="adults">Which insulin regimen is recommended for adults with type 1 diabetes?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 87dc6deb-8c56-4eb6-8f21-45f9d0951d22 --><!-- begin field 25e20eae-25ee-4910-9923-6377cc7eb0ee --><p><strong>Insuli</strong><strong>n therapy for adults with type 1 diabetes should only be initiated and managed by healthcare professionals with the relevant expertise and training.</strong> </p><ul><li><strong>Offer <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">multiple daily injection basal-bolus insulin regimens</a> as the first-line choice to all adults with type 1 diabetes.</strong><ul><li><strong>Offer twice-daily insulin detemir as the <a class="topic-reference internal-reference" href="index.html#available-insulin-products">long-acting</a> basal insulin therapy. </strong>However:<ul><li>If the person is achieving their agreed treatment target on an existing insulin regimen, continue on that regimen.</li><li>If twice-daily basal insulin injection is not acceptable to the person, consider once-daily insulin glargine or insulin detemir.</li><li>If insulin detemir is not tolerated, consider once-daily insulin glargine.</li><li>Consider other basal insulin regimens only if the recommendations above do not deliver agreed treatment targets. When choosing an alternative insulin regimen, take account of the person's preferences and the acquisition cost. </li></ul></li><li><strong>Offer a <a class="topic-reference internal-reference" href="index.html#available-insulin-products">rapid-acting</a> insulin analogue injected before meals for mealtime insulin replacement </strong>(rather than rapid-acting soluble human or animal insulins).<ul><li>Do not advise routine use of rapid-acting insulin analogues after meals.</li><li>If the person has a strong preference for an alternative mealtime insulin, offer their preferred choice. </li><li>Do not offer non-basal-bolus insulin regimens (that is, twice-daily mixed [biphasic], basal-only, or bolus-only regimens) to adults with newly diagnosed type 1 diabetes.</li></ul></li></ul></li><li><strong>If a multiple daily injection basal–bolus insulin regimen is not possible and a twice-daily <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">mixed insulin regimen</a> is preferred:</strong><ul><li>Consider a twice-daily human mixed insulin regimen.</li><li>Consider a trial of a twice-daily analogue mixed insulin regimen if the person has hypoglycaemia that affects their quality of life.</li></ul></li><li><strong><a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">Insulin pump&nbsp;therapy</a> is recommended as a treatment option for adults with type 1 diabetes mellitus if:</strong><ul><li>Attempts to achieve target HbA1c<sub> </sub>levels with multiple daily injection therapy result in the person experiencing disabling hypoglycaemia, <em>or</em></li><li>HbA1c<sub> </sub>levels have remained high (69 mmol/mol or above [8.5% or above]) during multiple daily injection therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care.</li></ul></li></ul><!-- end field 25e20eae-25ee-4910-9923-6377cc7eb0ee --><!-- end item 87dc6deb-8c56-4eb6-8f21-45f9d0951d22 --></div></section><section aria-labelledby="children-young-people" class="ChapterBody-module--wrapper--2HCfk "><h4 id="children-young-people">Which insulin regimen is recommended for children and young people with type 1 diabetes?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6c052dc8-4a31-45b7-91cf-845cf6571c2b --><!-- begin field 2af99947-d537-4033-9437-6bbb01725ff8 --><p><strong>Insulin therapy for children and young people with type 1 diabetes should only be initiated and managed by healthcare professionals with the relevant expertise and training. The choice of insulin regimen and <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">insulin delivery system</a> should take</strong><strong> into account the personal and family circumstances of the child or young person as well as their preference and that of their family/carers.</strong></p><ul><li><strong><a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">Multiple daily injection basal-bolus insulin regimens</a> should be offered to </strong><strong>children and young people with type 1 diabetes from diagnosis. </strong><ul><li>The child or young person and/or their family/carers should be:<ul><li>Encouraged to adjust the insulin dose if appropriate after each blood glucose measurement. </li><li>Advised that injecting a <a class="topic-reference internal-reference" href="index.html#available-insulin-products">rapid-acting</a> insulin analogue before eating (rather than after eating) reduces blood glucose levels after meals and helps to optimize blood glucose control.</li></ul></li></ul></li><li><strong>If a multiple daily injection basal-bolus insulin regime is unsuitable, </strong><a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">insulin pump&nbsp;therapy</a> may be considered as recommended in the National Institute for Health and Care Excellence (NICE) guidance <a data-hyperlink-id="6e2231d5-b263-4769-8163-abe8016324ce" href="http://www.nice.org.uk/guidance/TA151/chapter/1-guidance">Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus</a>.<ul><li>All children and young people with type 1 diabetes who are starting insulin pump therapy and/or their family/carers should be provided with specific training on its use.</li><li>Ongoing support from a specialist team should be provided, particularly in the period immediately after starting insulin pump therapy.</li><li>Specialist teams should agree a common core of advice for insulin pump users.</li></ul></li><li><strong>If the child or young person does not have optimal blood glucose control: </strong><ul><li>Appropriate additional support, such as increased contact frequency with their diabetes team, should be offered.</li><li>If necessary, an <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">alternative insulin regimen</a> should be offered.</li></ul></li><li><strong>Children and young people who are using a twice-daily injection regimen and/or their family/carers </strong>should be encouraged to adjust the insulin dose according to the general trend in pre-meal, bedtime, and occasional night-time blood glucose levels.</li></ul><!-- end field 2af99947-d537-4033-9437-6bbb01725ff8 --><!-- end item 6c052dc8-4a31-45b7-91cf-845cf6571c2b --></div></section><section aria-labelledby="basis-for-recommendation-397" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-397">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 397cf173-1852-47ad-b588-82acbed029aa --><!-- begin field 0c20ed2e-8188-45e3-9dd8-2b0e6a5975f0 --><p>This information is largely taken from the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016b</a>], and from information on the Diabetes UK website (<a href="http://www.diabetes.org.uk/" data-hyperlink-id="ea820372-aec7-46df-aceb-a931009aa7bf">www.diabetes.org.uk</a>) and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><ul><li>Information on the insulin pump is taken from the NICE Technology appraisal guidance C<em>ontinuous subcutaneous insulin infusion for the treatment of diabetes mellitus</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2008</a>].</li></ul><!-- end field 0c20ed2e-8188-45e3-9dd8-2b0e6a5975f0 --><!-- end item 397cf173-1852-47ad-b588-82acbed029aa --></div></section></section><section aria-labelledby="accessories-for-insulin-therapy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="accessories-for-insulin-therapy">What accessories are needed by a person on insulin therapy?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2750ee45-53c1-48ae-9e4f-2f77c52f2f3a --><!-- begin field d4b951f5-c289-479d-84af-646f77ae3978 --><ul><li><strong>Insulin injection device </strong><ul><li> A variety of insulin injection devices are available: standard insulin U100 syringes, preloaded disposable pens, reusable injection pens, needle-free injection devices, and <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">continuous subcutaneous insulin infusion (insulin pump) therapy</a>. </li><li>The choice of device will depend on factors such as:<ul><li>The age of the person.</li><li>Dexterity (for example ease of inserting and changing cartridges). </li><li>The presence of visual impairment (for example problems reading the dialled dose).</li><li>Inability to achieve target HbA1c — <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">insulin pump therapy</a> should be considered.</li><li>Needle phobia — needle-free insulin devices, such as <a href="https://insujet.com/" data-hyperlink-id="f02d4587-dd88-4248-8f71-abe600fe34b0">Insujet®</a> and <a href="http://www.injexuk.com/diabetes/" data-hyperlink-id="fead6ff8-3dd9-4088-8698-abe600fe3973">Injex®</a>, are possible options for people with true and severe needle phobia (which is rare).</li><li>Personal choice.</li></ul></li></ul></li><li><strong>Needles for pen injectors</strong><ul><li>Sterile disposable needles are available in different lengths (from 4 mm to 12.7 mm).</li><li>People having <a class="topic-reference internal-reference" href="index.html#managing-injection-site-problems">injection site problems</a> (such as pain, local skin reactions, and injection site leakages) should be offered needles of different lengths.</li><li>Children and young people should be provided with needles that are of appropriate length for their body fat.</li></ul></li><li><strong>Blood glucose meter, test strips, and lancets for <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">self-monitoring&nbsp;of blood glucose</a></strong><ul><li>Blood glucose monitoring meters are not prescribable on the NHS. However, some brands can be obtained free of charge from the diabetes specialist  team or the manufacturers; they can also be purchased online or from pharmacies. The choice of blood glucose meter will depend on personal preference, cost, and/or the policy of the diabetes specialist team.</li><li>Single-use testing strips are prescribable on the NHS, and they are designed for use with specific proprietary blood glucose monitoring meters.</li><li>Single-use lancets are also prescribable on the NHS. They are available in various lengths and gauges, and are designed to fit into proprietary finger-pricking devices (which are usually packaged with the blood glucose meter).</li></ul></li><li><strong>Ketone meter, test strips, and lancets </strong><ul><li>Blood ketone meters are not prescribable on the NHS but can be purchased online or from pharmacies. Single-use blood ketone testing strips and single-use lancets are available on the NHS. </li><li>Urine ketone testing strips are available on the NHS. </li></ul></li><li><strong>Glucose and/or glucagon kit </strong>(for treating <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglycaemia</a>)<ul><li>Glucose 40% oral gel is available on prescription (and can also be purchased from pharmacies) for the treatment of <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglycaemia</a> in people who are able to swallow safely.</li><li>Glucagon 1 mg injection (GlucaGen<sup>® </sup>Hypokit) is available on prescription for the treatment of severe hypoglycaemia.</li></ul></li><li><strong>Accessories for sharps disposal </strong><ul><li>Used syringes, insulin pen devices (such as pre-filled pens), needles, and lancets must be safely stored and disposed of to prevent sharps-related injuries. </li><li>Needle-clipping (chopping) devices are available on the NHS and are designed to clip the needle off the insulin pen after use.</li><li>Sharps containers are also available on the NHS and come in different sizes. <ul><li>A 1 L sharps bin is suitable for most people.</li><li>A 5 L sharps bin is most suitable for people who have lancets, insulin pen needles, syringes, and insulin pump tubing and cannulas to dispose of. </li></ul></li></ul></li><li><strong>Insulin Passport and patient information booklet </strong><ul><li>The Insulin Passport provides a record of the person's current insulin preparations, and contains a section for emergency information.</li><li>The patient information booklet provides advice on the safe use of insulin.</li><li>Adults on insulin therapy should be given a patient information booklet and an Insulin Passport.<ul><li>GP practices can obtain supplies of both documents through their Local Area Team stores. They can also be purchased from 3M Security Print and Systems Limited, Gorse Street, Chadderton, Oldham, OL9 9QH (telephone: 0845 610 1112).</li></ul></li></ul></li><li><strong>Identification jewellery or card </strong><ul><li>People with diabetes should be advised to always carry some form of identification indicating that they have diabetes. Examples include:<ul><li>MedicAlert® bracelet, necklace, or watch (available from <a href="http://www.medicalert.org.uk/" data-hyperlink-id="b51bd531-0794-480a-8bd3-abe600faa71b">www.medicalert.org.uk</a>).</li><li>Diabetes ID Card (available from <a href="https://www.diabetes.co.uk/diabetic-products/medipal-card.html" data-hyperlink-id="c384f32f-b5a0-45c3-8fd0-abe600faa744">www.diabetes.co.uk</a>).</li></ul></li></ul></li></ul><!-- end field d4b951f5-c289-479d-84af-646f77ae3978 --><!-- end item 2750ee45-53c1-48ae-9e4f-2f77c52f2f3a --></div><section aria-labelledby="basis-for-recommendation-65b" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-65b">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 65b798de-b616-49d9-9949-12292b0542e3 --><!-- begin field 32405989-d330-442e-b3c1-d4be6dc4ee46 --><p>This information is largely taken from the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016b</a>], and from information on the Diabetes UK website (<a href="http://www.diabetes.org.uk/" data-hyperlink-id="ea820372-aec7-46df-aceb-a931009aa7bf">www.diabetes.org.uk</a>) and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field 32405989-d330-442e-b3c1-d4be6dc4ee46 --><!-- end item 65b798de-b616-49d9-9949-12292b0542e3 --></div></section></section><section aria-labelledby="administration" class="ChapterBody-module--wrapper--2HCfk "><h3 id="administration">How is insulin administered?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d7ff30e4-1237-4e2f-922b-59fe8d867e84 --><!-- begin field 7b26e65d-85e8-452b-80b8-23612eb725ac --><ul><li><strong>Insulin preparations are usually given by subcutaneous injection because insulin is destroyed by gastric acid and is not absorbed across the gut mucosa. </strong>For some people, insulin is given by subcutaneous infusion via an <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">insulin pump</a>.</li><li><strong>There is considerable day-to-day variation in insulin absorption, particularly in children.</strong><ul><li>The rate of absorption can vary by as much as 20–40% from one day to the next in any person, owing to local tissue reactions, changes in insulin sensitivity, blood flow, depth of injection, and/or the amount of insulin injected.</li><li>Other factors that affect insulin absorption include:<ul><li>Larger dose — absorption is slower if a large insulin dose is injected.</li><li>Accidental intramuscular injection (due to poor <a class="topic-reference internal-reference" href="index.html#injection-technique">injection technique</a> or the use of an inappropriate needle length) — injecting insulin into deeper intramuscular tissue can increase the variability of absorption and cause erratic blood glucose levels and hypoglycaemia. </li><li>Exercise — absorption is faster owing to increased blood flow at the injection site of the exercised region (for example thighs of runners).</li><li><a class="topic-reference internal-reference" href="index.html#injection-site">Injection site</a> — the rate of insulin absorption varies depending on which part of the body is used. This might have some effect on blood glucose control. </li><li>Age — absorption is faster in young children as they have less subcutaneous fat.</li><li>Fat mass — absorption is slower if there is a large amount of subcutaneous fat.</li></ul></li></ul></li></ul><!-- end field 7b26e65d-85e8-452b-80b8-23612eb725ac --><!-- end item d7ff30e4-1237-4e2f-922b-59fe8d867e84 --></div><section aria-labelledby="basis-for-recommendation-ee5" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ee5">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ee57f16c-075c-43b4-b14d-3bdd527c9111 --><!-- begin field 08235048-bdfe-4137-9ebe-6e081cf960b1 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>] and the <em>ISPAD Clinical Practice Consensus Guidelines 2018: insulin treatment in children and adolescents with diabetes</em> published by the International Society for Pediatric and Adolescent Diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>]. Recommendations have also been extrapolated from the Royal College of Nursing guideline <em>Starting injectable treatment in adults with Type 2 diabetes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</p><!-- end field 08235048-bdfe-4137-9ebe-6e081cf960b1 --><!-- end item ee57f16c-075c-43b4-b14d-3bdd527c9111 --></div></section></section><section aria-labelledby="injection-technique" class="ChapterBody-module--wrapper--2HCfk "><h3 id="injection-technique">What should I advise on injection technique for insulin therapy?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f1102482-a09a-4e96-9c02-abe60135069e --><!-- begin field 3aa06912-0e66-4ea4-9924-abe6013a5d7e --><p><strong>Advise the person:</strong></p><ul><li>To leave insulin at room temperature for at least 30 minutes before injecting.<ul><li>A longer period may be required for some insulins — advise the person to check the manufacturer's patient information leaflet (PIL).</li><li>Cold insulin (straight from the fridge) can make injection painful, and the insulin may take longer to absorb.</li></ul></li><li>To check the expiry date of the product before administration.</li><li>To carefully read the manufacturer's PIL (or get advice from their diabetes specialist team) on how to use their specific product, including:<ul><li>How to prepare the insulin before use.<ul><li>If using cloudy insulin, they should invert or rotate (not shake) the pen at least 10 times in the palm of the hands and invert 10 times to mix the insulin. </li></ul></li><li>How to prime the pen, if needed.<ul><li>This should be done before each injection, to ensure that the plunger is connecting and any air is expelled from the pen.</li></ul></li></ul></li><li>To use a new needle for each injection.</li><li>To choose an appropriate <a class="topic-reference internal-reference" href="index.html#injection-site">injection site</a>, ensuring that the site and hands are clean. <ul><li>Unless hygiene is a real problem, the use of alcohol wipes should be avoided as it can make the injection more painful and harden the skin. Infection at injection sites is rare.</li><li>Injections should not be done through clothing as this will affect lubrication of the needle and also make it difficult to 'pinch up' the skin and to check for bleeding.</li><li>For people injecting more than 50 units of insulin (0.5 mL of U100 insulin), many experts recommend splitting the injection into separate areas to facilitate absorption.</li></ul></li><li>That insulin should be injected with the needle at a 90° angle to the skin. The needle should be inserted quickly and all the way in to ensure injection at a consistent depth.<ul><li>People using long needles (longer than 8 mm) might have to inject at an angle less than 90° to avoid injecting into the muscle (or perhaps are better switching to a shorter needle).</li><li>The needle should be left in the skin for 5–10 seconds (or longer for large doses) to ensure the entire dose is injected and to avoid leakage of the dose.</li></ul></li><li>That after withdrawing the needle, they should apply gentle pressure over the injection site for several seconds. The area should not be rubbed as this may increase the rate of insulin absorption.</li><li>To <a class="topic-reference internal-reference" href="index.html#storage-of-insulin">store</a> their insulin properly.</li></ul><!-- end field 3aa06912-0e66-4ea4-9924-abe6013a5d7e --><!-- end item f1102482-a09a-4e96-9c02-abe60135069e --></div><section aria-labelledby="basis-for-recommendation-b71" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-b71">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b71b9b75-6ec6-4d66-bc25-abe6013506f8 --><!-- begin field be1ea7d8-eab1-4033-acc8-abe6013506f8 --><p>These recommendations are based on the <em>ISPAD Clinical Practice Consensus Guidelines 2018: insulin treatment in children and adolescents with diabetes</em> published by the International Society for Pediatric and Adolescent Diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], information on the Diabetes UK website (<a href="http://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/insulin" data-hyperlink-id="e7e33d72-05ac-4651-835a-abfa01453ac2">www.diabetes.org.uk</a>), and on expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hendra, 2002</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Wallymahmed, 2006</a>]. Recommendations have also been extrapolated from the Royal College of Nursing guideline <em>Starting injectable treatment in adults with Type 2 diabetes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</p><!-- end field be1ea7d8-eab1-4033-acc8-abe6013506f8 --><!-- end item b71b9b75-6ec6-4d66-bc25-abe6013506f8 --></div></section></section><section aria-labelledby="injection-site" class="ChapterBody-module--wrapper--2HCfk "><h3 id="injection-site">What should I advise on injection sites for insulin therapy?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e253fc43-0dcb-4c01-b3cd-b92bccb44271 --><!-- begin field c5a7349c-c380-435a-aee1-32630e93892a --><p><strong>Advise the person:</strong></p><ul><li>To choose a body area that has plenty of subcutaneous fat, ensuring that the site and hands are clean. The main injection sites are:<ul><li>Abdomen — fastest absorption rate compared with other sites.</li><li>Outer thigh — absorption rate slower than abdomen.</li><li>Buttocks — absorption rate slowest compared with abdomen and thigh. This site may be useful in small children.</li><li>Arm (not usually recommended due to the difficulty in injecting at this site) — absorption rate medium to fast.</li></ul></li><li>That if necessary, the skin should be 'pinched up' to avoid injecting into the muscle. This is recommended especially for slim people, for injection sites that have little subcutaneous fat, and when using long needles. <ul><li>Pinching up may not be necessary:<ul><li>When using a very short needle (for example 4 mm needle).</li><li>If the buttocks are used, due to the abundance of subcutaneous fat.</li></ul></li></ul></li><li>That injection sites should be:<ul><li>Checked regularly for lumps (<a class="topic-reference internal-reference" href="index.html#managing-injection-site-problems">lipohypertrophy</a>) and other <a class="topic-reference internal-reference" href="index.html#managing-injection-site-problems">injection site problems</a>.</li><li>Rotated to prevent lipohypertrophy. Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections as sites with these reactions. and cutaneous amyloidosis — advise that there may be delayed insulin absorption following insulin injections at sites with these reactions.<ul><li>The person should alternate between the left and right side of the body on a weekly basis.</li><li>Injection sites can be rotated within the same area. Each injection should be at least one finger's breadth away from the site of the previous injection.</li><li>Rotation grids (available from manufacturers of insulin syringes and needles) may be helpful for some people who have problems rotating injection sites.</li></ul></li></ul></li></ul><!-- end field c5a7349c-c380-435a-aee1-32630e93892a --><!-- end item e253fc43-0dcb-4c01-b3cd-b92bccb44271 --></div><section aria-labelledby="basis-for-recommendation-ecd" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ecd">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ecdc12b7-896b-4325-ba91-d7b15564459d --><!-- begin field 7bd25edf-1520-4977-9bbc-399ee8c4bcf0 --><p>These recommendations are based largely on the <em>Clinical Practice Consensus Guidelines 2018: insulin treatment in children and adolescents with diabetes</em> published by the International Society for Pediatric and Adolescent Diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], information on the Diabetes.org.uk website (<a href="https://www.diabetes.co.uk/insulin/injection-sites.html" data-hyperlink-id="fa3e7185-670c-466d-a144-abe8017f4aef">www.diabetes.org.uk</a>), and on information from manufacturer's summary of product characteristics (SPC) [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>]. Recommendations have also been extrapolated from the Royal College of Nursing guideline <em>Starting injectable treatment in adults with Type 2 diabetes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</p><!-- end field 7bd25edf-1520-4977-9bbc-399ee8c4bcf0 --><!-- end item ecdc12b7-896b-4325-ba91-d7b15564459d --></div></section></section><section aria-labelledby="storage-of-insulin" class="ChapterBody-module--wrapper--2HCfk "><h3 id="storage-of-insulin">What should I advise on the storage of insulin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a87192ae-5e40-4c76-b30d-700d6935d107 --><!-- begin field 31144139-61d3-4721-a7d4-e90a73527426 --><p><strong>Advise the person that:</strong></p><ul><li>Insulin that is not currently being used should be stored in a refrigerator (2–8°C).<ul><li>The person should keep at least one spare insulin vial or cartridge of each type of prescribed insulin.</li></ul></li><li>Insulin must not become frozen; it should be discarded if this occurs.<ul><li>Vials or pens should not be stored in, or too near to, the freezer section or cooling element of the refrigerator.</li></ul></li><li>They should check the manufacturer's patient information leaflet for specific storage information.<ul><li>Once in use, in general, insulin can be stored at room temperature for 28 days (some insulins may be stable for longer).  </li><li>Insulin must be protected from sunlight and excessive heat (for example it should not be placed near a cooker, on top of electrical equipment, or left in a car during hot weather).</li></ul></li></ul><!-- end field 31144139-61d3-4721-a7d4-e90a73527426 --><!-- end item a87192ae-5e40-4c76-b30d-700d6935d107 --></div><section aria-labelledby="basis-for-recommendation-239" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-239">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 23955ddd-5acd-4690-b4e9-8363b75774f1 --><!-- begin field f05f86f0-0906-4926-9e13-a7c0e0d9741e --><p>These recommendations are based largely on the <em>Clinical Practice Consensus Guidelines 2018: insulin treatment in children and adolescents with diabetes</em> published by the International Society for Pediatric and Adolescent Diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>] and on information on the Diabetes.org.uk website (<a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/insulin" data-hyperlink-id="482f3f20-8163-4f0f-8db3-abe601580825">www.diabetes.org.uk</a>). Recommendations have also been extrapolated from the Royal College of Nursing guideline <em>Starting injectable treatment in adults with Type 2 diabetes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</p><!-- end field f05f86f0-0906-4926-9e13-a7c0e0d9741e --><!-- end item 23955ddd-5acd-4690-b4e9-8363b75774f1 --></div></section></section><section aria-labelledby="self-monitoring-of-blood-glucose" class="ChapterBody-module--wrapper--2HCfk "><h3 id="self-monitoring-of-blood-glucose">What should I advise on self-monitoring of blood glucose?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8ff3aac2-67b0-4420-b55a-abf90171f78f --><!-- begin field 99a31e57-1236-47a9-ac28-abf90171f855 --><ul><li><strong>Self-monitoring of blood glucose refers to home blood glucose testing for people with diabetes to determine the amount of glucose in the blood at any given time. </strong><ul><li>To self-monitor, the person would need a blood glucose monitor, lancets (which fit into a finger-pricking device), and testing strips (on which the blood is collected for testing in the machine).</li><li>See the sections on <a class="topic-reference internal-reference" href="index.html#target-levels-adults">Target levels - Adults</a> and <a class="topic-reference internal-reference" href="index.html#target-levels-children-young-people">Target levels - Children and young people</a> for information on blood glucose self-monitoring target levels.</li></ul></li><li><strong>Self-monitoring skills should be taught at the time of diagnosis and at the time of initiation of insulin therapy, and should be reviewed at least annually. </strong>The review should include checking that the person knows:<ul><li>How to use their blood glucose monitoring meter — this can be done by asking them to demonstrate their technique.</li><li>When to test — for example before breakfast and 2 hours after meals, during periods of illness, before driving, and if they feel hypoglycaemic. </li><li>How to assess and respond to test results, including how to:<ul><li>Interpret trends in blood glucose levels as well as individual readings — this is important for adjusting insulin doses.</li><li>Identify the causes of high and low blood glucose values.</li></ul></li></ul></li><li><strong>Continuous glucose monitoring is a way of measuring glucose levels continuously throughout the day and night via a tiny electrode inserted under the skin. </strong><ul><li>Continuous glucose monitoring systems provide continuous measurements (every 1–5 minutes) of glucose concentrations in the interstitial fluid, which correlate with blood glucose levels. They can provide both retrospective and real-time information to detect hypoglycaemic and hyperglycaemic episodes, predict impending hypoglycaemia, and detect wide fluctuations in glucose levels (glycaemic variability).</li><li>Continuous glucose monitoring is not routinely recommended for people with type 1 diabetes but may be considered in certain circumstances. See the sections on <a class="topic-reference internal-reference" href="index.html#target-levels-adults">Target levels - Adults</a> and <a class="topic-reference internal-reference" href="index.html#target-levels-children-young-people">Target levels - Children and young people</a> for information on when continuous glucose monitoring should be considered.</li></ul></li></ul><!-- end field 99a31e57-1236-47a9-ac28-abf90171f855 --><!-- end item 8ff3aac2-67b0-4420-b55a-abf90171f78f --></div><section aria-labelledby="target-levels-adults" class="ChapterBody-module--wrapper--2HCfk "><h4 id="target-levels-adults">What are the target blood glucose self-monitoring levels for adults with type 1 diabetes?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f151dd12-0c61-4064-aa00-abf901731ff1 --><!-- begin field 887f5718-30bf-4594-b395-abf901732054 --><ul><li><strong>Advise routine self-monitoring of blood glucose levels at least 4 times a day (including before meals and before bed). </strong><ul><li>More frequent monitoring (up to 10 times a day or more) may be required if any of the following apply: <ul><li>The target HbA1c level is not achieved. See the section on <a class="topic-reference external-reference" href="../../../diabetes-type-1/management/management-adults/index.html#target-hba1c">Target HbA1c&nbsp;- Adults</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-1/index.html">Diabetes - type 1</a> for information on target HbA1c levels.</li><li>The frequency of <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglycaemic episodes</a> increases. </li><li>There is a legal requirement to do so, such as before driving. </li><li>During periods of illness.</li><li>Before, during, and after<strong><em> </em></strong>sport.</li><li>When planning a pregnancy, during pregnancy, and while breastfeeding. See the National Institute for Health and Care Excellence (NICE) guideline on <a data-hyperlink-id="7b5c7376-383d-4468-9fa8-a93100987b6c" href="https://www.nice.org.uk/guidance/ng3">Diabetes in pregnancy</a> for more information.</li><li>If there is a need to know blood glucose levels more than 4 times a day for other reasons, for example in people with <a class="topic-reference internal-reference" href="index.html#impaired-awareness-of-hypoglycaemia">impaired awareness of hypoglycaemia</a>. </li><li>If it is necessary because of the person’s lifestyle, for example they drive for a long period of time, undertake a high-risk activity or occupation, or travel frequently or across time zones.</li></ul></li></ul></li><li><strong>Discuss optimal targets for glucose self-monitoring.</strong><ul><li><strong>The optimal targets for glucose self-monitoring in adults with type 1 diabetes are: </strong><ul><li>Fasting plasma glucose level of 5–7 mmol/L on waking.</li><li>Plasma glucose level of 4–7 mmol/L before meals at other times of the day.</li><li>For adults who choose to test after meals, plasma glucose level of 5–9 mmol/L at least 90 minutes after eating. </li></ul></li><li>Agree bedtime target plasma glucose levels with the person. This should:<ul><li>Take into account the timing of the last meal and its related insulin dose.</li><li>Be consistent with the recommended fasting level on waking.</li></ul></li><li>Remind them of the need to be particularly careful to avoid hypoglycaemia when driving. </li></ul></li><li><strong><a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">Continuous glucose monitoring</a> is not routinely recommended for adults with type 1 diabetes. </strong><ul><li>NICE recommends that real-time continuous glucose monitoring may be considered for adults with one or more of the following:<ul><li>Extreme fear of hypoglycaemia. </li><li>More than one episode a year of severe hypoglycaemia with no obvious cause.</li><li>Complete loss of awareness of hypoglycaemia.</li><li>Persistent hyperglycaemia (HbA1c of 75 mmol/mol or higher) despite testing at least 10 times a day.</li><li>Frequent (more than two episodes) of asymptomatic hypoglycaemia.</li></ul></li><li>The person must be willing to commit to using it at least 70% of the time and to calibrate it as needed.</li></ul></li></ul><!-- end field 887f5718-30bf-4594-b395-abf901732054 --><!-- end item f151dd12-0c61-4064-aa00-abf901731ff1 --></div></section><section aria-labelledby="target-levels-children-young-people" class="ChapterBody-module--wrapper--2HCfk "><h4 id="target-levels-children-young-people">What are the target blood glucose self-monitoring levels for children and young people with type 1 diabetes?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fbc1a4a2-5f68-4f13-a7aa-abf90173346a --><!-- begin field 61905fc7-ec7d-4047-bec9-abf9017334cb --><ul><li><strong>For children and young people with type 1 diabetes, advise routine self-monitoring of blood glucose levels by performing at least 5 capillary blood glucose tests per day. </strong><ul><li>Advise the child or young people and/or their family/carers that more frequent testing is often needed (for example with physical activity and during intercurrent illness), and ensure they have enough test strips for this. </li><li>Offer a choice of equipment for monitoring capillary blood glucose so that they can optimize their blood glucose control in response to adjustment of insulin, diet, and exercise. </li></ul></li><li><strong>The optimal targets for glucose self-monitoring in children and young people with type 1 diabetes are: </strong><ul><li>Fasting plasma glucose level of 4–7 mmol/L on waking.</li><li>Plasma glucose level of 4–7 mmol/L before meals at other times of the day.</li><li>Plasma glucose level of 5–9 mmol/L after meals.</li><li>For young people of driving age, plasma glucose level of at least 5 mmol/L when driving.</li></ul></li><li><strong>Explain that achieving and maintaining blood glucose levels towards the lower end of the target optimal ranges will help them to achieve the lowest attainable HbA1c. </strong>See the section on <a class="topic-reference external-reference" href="../../../diabetes-type-1/management/management-children-young-people/index.html#target-hba1c">Target HbA1c&nbsp;- Children and young people</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-1/index.html">Diabetes - type 1</a> for information on target HbA1c levels.<ul><li>Ensure that children and young people do not experience problematic hypoglycaemia or undue emotional distress when achieving, or attempting to achieve, blood glucose targets. </li><li>Be aware that there may be conflict between the child or young person and their family members or carers about blood glucose targets and that an agreed compromise may be needed.</li><li>Explain that blood glucose levels should be interpreted in the context of the 'whole child', which includes the social, emotional, and physical environment. </li></ul></li><li><strong><a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">Continuous glucose monitoring</a> is not currently recommended for all children and young people with type 1 diabetes. </strong>The National Institute for Health and Care Excellence (NICE) recommends that:<ul><li>Ongoing real-time continuous glucose monitoring with alarms may be offered to children and young people with type 1 diabetes who have one or more of the following:<ul><li>Frequent severe hypoglycaemia.</li><li>Impaired awareness of hypoglycaemia associated with adverse consequences (for example seizures or anxiety).</li><li>Inability to recognize, or communicate about, symptoms of hypoglycaemia (for example because of cognitive or neurological disabilities).</li></ul></li><li>Ongoing real-time continuous glucose monitoring may be considered for:<ul><li>Neonates, infants, and pre-school children.</li><li>Children and young people who undertake high levels of physical activity (for example sport at a regional, national, or international level).</li><li>Children and young people who have comorbidities (for example anorexia nervosa) or who are receiving treatments (for example corticosteroids) that can make blood glucose control difficult.</li></ul></li><li>Intermittent (real-time or retrospective) continuous glucose monitoring may be considered to help improve blood glucose control in children and young people who continue to have hyperglycaemia despite insulin adjustment and additional support.</li></ul></li></ul><!-- end field 61905fc7-ec7d-4047-bec9-abf9017334cb --><!-- end item fbc1a4a2-5f68-4f13-a7aa-abf90173346a --></div></section><section aria-labelledby="basis-for-recommendation-738" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-738">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 738dce0c-73db-4036-ba64-abf90171f85c --><!-- begin field 584db3a6-ce69-41a8-a1f3-abf90171f85c --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016b</a>]. The definition of continuous glucose monitoring is taken from review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Edelman, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ajjan, 2019</a>].</p><!-- end field 584db3a6-ce69-41a8-a1f3-abf90171f85c --><!-- end item 738dce0c-73db-4036-ba64-abf90171f85c --></div></section></section><section aria-labelledby="managing-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-hypoglycaemia">What should I advise on the management of hypoglycaemia?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 72852216-e8a9-42db-a03e-32322c220c5a --><!-- begin field 34a3d5dd-5353-40a4-9ec2-94a39e6b1d11 --><ul><li><strong>Hypoglycaemia is an inevitable adverse effect of insulin therapy.</strong> It is generally defined as being present when blood glucose levels fall to less than 3.5 mmol/L. However, the absolute blood glucose level at which signs and symptoms begin to occur can vary.<ul><li>The severity of hypoglycaemia is defined by the clinical manifestations:<ul><li>Mild hypoglycaemia presents with a wide variety of symptoms, including hunger, anxiety or irritability, palpitations, sweating, or tingling lips.</li><li>As the blood glucose levels fall lower, the person may experience weakness and lethargy, impaired vision, and confusion or irrational behaviour. Cognitive function deteriorates when blood glucose levels fall to less than 3.0 mmol/L.</li><li>Severe hypoglycaemia may result in convulsions, loss of consciousness, and coma. People with severe hypoglycaemia are unable to self-manage a hypoglycaemic episode and require help from another person to achieve normoglycaemia.</li></ul></li></ul></li><li><strong>Ensure that people on insulin therapy and/or their family/carers are given appropriate information on hypoglycaemia, including information on:</strong><ul><li>Awareness and <a class="topic-reference internal-reference" href="index.html#managing-an-episode-of-hypoglycaemia">management</a> of hypoglycaemia. </li><li><a class="topic-reference internal-reference" href="index.html#driving">Driving and hypoglycaemia</a>, in line with recommendations from the Driver and Vehicle Licensing Agency (DVLA).  </li></ul></li><li><strong>If hypoglycaemia becomes unusually problematic or of increased frequency, </strong>review the following possible contributory causes:<ul><li>Inappropriate <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">insulin regimens</a> (incorrect dose distributions and insulin types). Consider referring the person for a review of their current insulin regimen.</li><li>Lifestyle issues, including meal and activity pattern, and alcohol intake.</li><li><a class="topic-reference internal-reference" href="index.html#injection-technique">Injection technique</a> and skills.</li><li><a class="topic-reference internal-reference" href="index.html#managing-injection-site-problems">Injection site problems</a>.</li><li><a class="topic-reference internal-reference" href="index.html#impaired-awareness-of-hypoglycaemia">Impaired awareness of hypoglycaemia</a>.</li><li>Changes in insulin sensitivity — an insulin-sensitive person will require smaller amounts of insulin to lower blood glucose levels than a person who has low sensitivity.</li><li>Previous physical activity.</li><li>Drug interactions — some <a class="topic-reference internal-reference" href="index.html#drug-interactions">drugs</a> can enhance the hypoglycaemic effects of insulin.</li><li>Lack of appropriate knowledge and skills for self-management.</li><li>Possible organic causes —  suspect comorbidities such as hyperthyroidism, coeliac disease, Addison's disease, and chronic kidney disease in people with erratic blood glucose control. Suspect gastroparesis if the person also has unexplained bloating or vomiting.</li><li>Psychological problems — anxiety, depression, eating disorders, behavioural and conduct disorders, relationship problems, and poor psychosocial support can greatly affect the management of diabetes and the person's wellbeing. Refer the person to an appropriate mental health professional if necessary.</li></ul></li><li><strong>For adults with recurrent episodes of hypoglycaemia,</strong> consider the Blood Glucose Awareness Training (BGAT) programme (an online educational programme for improving hypoglycaemia and blood glucose awareness). </li><li><strong>For adults with recurrent severe hypoglycaemia that has not responded to other treatments,</strong> consider referring them to a centre that assesses people for islet and/or pancreas transplantation.</li><li><strong>If the person is experiencing symptoms of nocturnal hypoglycaemia (fatigue, headache, or a hangover sensation) or if this is detected on monitoring: </strong><ul><li>Review their knowledge and self-management skills.</li><li>Review their current insulin regimen, evening eating habits, and previous physical activity.</li><li>Advise them to:<ul><li>Occasionally check their blood glucose between 2 am and 3 am, when hypoglycaemia is most likely to happen. </li><li>Eat a snack before bedtime and keep a source of <a class="topic-reference internal-reference" href="index.html#managing-an-episode-of-hypoglycaemia">fast-acting carbohydrate</a> next to the bed.</li></ul></li><li>Consider referring the person to their diabetes specialist team for a review of their current insulin regimen.</li></ul></li></ul><!-- end field 34a3d5dd-5353-40a4-9ec2-94a39e6b1d11 --><!-- end item 72852216-e8a9-42db-a03e-32322c220c5a --></div><section aria-labelledby="managing-an-episode-of-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h4 id="managing-an-episode-of-hypoglycaemia">Managing an episode of hypoglycaemia</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d9f173cb-0c55-44b0-b153-b05c8ed3068d --><!-- begin field d4a2b763-5eae-449d-8c04-e6ef7bab696f --><ul><li><strong>People with hypoglycaemia who are able to swallow should:</strong><ul><li><strong>Promptly consume 10–20 g of a fast-acting form of carbohydrate, </strong>preferably in liquid form as this is easier to take. It may be necessary to give the carbohydrate in small amounts as hypoglycaemia may cause vomiting.<ul><li>As a guide for children and young people, approximately 0.3 g/kg of fast-acting carbohydrate should be given.</li><li><strong>In general, 10–20 g of fast-acting carbohydrate corresponds to the following: </strong>3–6 glucose tablets; 90–180 mL of fizzy drink or squash (not the sugar-free or reduced-sugar versions); 50–100 mL of Lucozade Energy<sup>® </sup>(contains 26% glucose syrup per 100 mL); 2–4 spoonfuls of sugar added to a cup of drink (for example water); sweets, such as four large jelly babies or seven large jelly beans; and 1–2 two tubes of Dextrogel<sup>® </sup>(contains 10 g of glucose and is available on prescription or can be purchased over the counter).</li><li>Chocolates and biscuits should be avoided if possible because they have a lower sugar content and their high fat content may delay stomach emptying.</li></ul></li><li><strong>Recheck blood glucose levels after 10–15 minutes.</strong><ul><li>Hypoglycaemia should be reversed in about 10 minutes as simple carbohydrates are expected to raise blood glucose levels within 5–15 minutes.</li><li>Improvements in signs and symptoms may lag behind improvement in blood glucose level.</li></ul></li><li><strong>If there is no response or an inadequate response, </strong>repeat oral intake as above and re-test blood glucose levels after another 15 minutes.</li><li><strong>When symptoms improve or normoglycaemia is restored:</strong><ul><li>If the next meal is due, the carbohydrate intake of that meal should be increased (for example with bread, potatoes, or pasta).</li><li>If the next meal is not due soon, the person should immediately eat some long-acting starchy carbohydrate (such as a sandwich or some biscuits) to maintain blood glucose. This is not necessary for people on a <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">continuous subcutaneous insulin infusion (insulin pump therapy)</a>.</li></ul></li></ul></li><li><strong>If the person is unconscious and unable to swallow (severe hypoglycaemia):</strong><ul><li><strong>Intramuscular (IM) glucagon should be administered immediately.</strong><ul><li>For children younger than 8 years of age (or body weight less than 25 kg), 500 micrograms of glucagon should be given.</li><li>For all other people, 1 mg of glucagon should be given.</li></ul></li><li><strong>Emergency transfer to hospital should be arranged (by calling 999) if:</strong><ul><li>IM glucagon is not available. </li><li>The family members/carers are not trained to administer glucagon. </li><li>Alcohol is the cause of, or has contributed to, the development of hypoglycaemia (intravenous [IV] glucose is required).</li></ul></li><li><strong>If the person does not respond to glucagon treatment within 10 minutes, </strong>emergency transfer to hospital should be arranged for treatment with IV glucose.</li><li><div><strong>If the person responds to glucagon treatment within 10 minutes and is sufficiently awake and able to swallow safely,</strong> they should eat some oral carbohydrate (to replace the body's supply and to prevent relapse of hypoglycaemia).</div><ul><li>Vomiting is common in the recovery phase, and recurrent hypoglycaemia may recur. Consequently, the person should be closely monitored with regular checking of blood glucose.</li><li>If hypoglycaemia recurs, the person may require additional oral carbohydrate or urgent hospital admission for treatment with IV glucose (if symptoms are severe).</li></ul></li></ul></li></ul><!-- end field d4a2b763-5eae-449d-8c04-e6ef7bab696f --><!-- end item d9f173cb-0c55-44b0-b153-b05c8ed3068d --></div></section><section aria-labelledby="impaired-awareness-of-hypoglycaemia" class="ChapterBody-module--wrapper--2HCfk "><h4 id="impaired-awareness-of-hypoglycaemia">Managing a person with impaired awareness of hypoglycaemia</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0ed51146-847b-4bdf-910e-f44e9e78bba7 --><!-- begin field eaebad5d-ad39-4a5d-b94a-64c55b973ab8 --><ul><li><strong>Impaired awareness of hypoglycaemia </strong>occurs when a person loses the ability to recognize the usual <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">symptoms</a> of hypoglycaemia, or when these symptoms are absent or blunted.</li><li><strong>At each annual review, </strong>use the Gold or Clarke score to quantify awareness of hypoglycaemia in adults with type 1 diabetes, checking that the questionnaire items have been completed correctly.</li><li><strong>To manage impaired awareness of hypoglycaemia:</strong><ul><li>Ensure that the person and/or their family/carers have had appropriate education on insulin therapy and that they are following the principles correctly.<ul><li>Offer additional education focusing on avoiding and treating hypoglycaemia if the person continues to have impaired awareness of hypoglycaemia. See the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-1/index.html">Diabetes - Type 1</a> for information on education for people with type 1 diabetes and/or their family/carers.</li></ul></li><li>Explain that impaired awareness of the symptoms of blood glucose levels below 3 mmol/L is associated with a significantly increased risk of severe hypoglycaemia (hypoglycaemic episode in which the person requires help from another person to achieve normoglycaemia).</li><li>Review insulin regimens and doses and prioritize strategies to avoid hypoglycaemia.<ul><li>If the person's target blood glucose levels are lower than recommended, reinforce the recommended treatment targets.</li></ul></li><li>Avoid relaxing individualized blood glucose targets as a treatment for hypoglycaemia unawareness.</li></ul></li><li><strong>Refer to the diabetes specialist team for consideration of <a class="topic-reference internal-reference" href="index.html#recommended-insulin-regimen">continuous subcutaneous insulin infusion (insulin pump therapy)</a> or <a class="topic-reference internal-reference" href="index.html#self-monitoring-of-blood-glucose">continuous glucose monitoring</a> if:</strong><ul><li>The person continues to have impaired awareness of hypoglycaemia.</li><li>Impaired awareness of hypoglycaemia is associated with recurrent severe hypoglycaemia despite these interventions.</li></ul></li></ul><!-- end field eaebad5d-ad39-4a5d-b94a-64c55b973ab8 --><!-- end item 0ed51146-847b-4bdf-910e-f44e9e78bba7 --></div></section><section aria-labelledby="basis-for-recommendation-521" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-521">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 52140ab7-9d2c-481d-8576-ec84ea51475f --><!-- begin field b458e13f-011d-4d37-8819-d662a8273256 --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015c</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016b</a>], and on information on the Diabetes UK website (<a href="http://www.diabetes.org.uk/" data-hyperlink-id="ea820372-aec7-46df-aceb-a931009aa7bf">www.diabetes.org.uk</a>) and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><ul><li>The recommendation on alcohol-related hypoglycaemia is also based on the Summary of Product Characteristics (SPC) for GlucaGen Hypokit 1mg, which states that glucagon has 'little or no effect' when a person is experiencing alcohol-induced hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020c</a>].</li><li>The information on nocturnal hypoglycaemia is also based on expert opinion in a review article, which states that [<a class="bibliography-reference internal-reference" href="../../references/index.html">Graveling, 2017</a>]:<ul><li>Cardiac arrhythmias that occur during nocturnal hypoglycaemia include bradycardia and ectopics that may provoke dangerous arrhythmias. </li><li>Nocturnal hypoglycaemia is associated with great morbidity and mortality, causing seizures, coma, and cardiovascular events and affecting quality of life, mood, and work performance the following day. It may also induce impaired awareness of hypoglycaemia.</li><li>Over 50% of all episodes of severe hypoglycaemia (requiring external help) occur during sleep, but nocturnal hypoglycaemia is often asymptomatic and unrecognized. </li></ul></li></ul><!-- end field b458e13f-011d-4d37-8819-d662a8273256 --><!-- end item 52140ab7-9d2c-481d-8576-ec84ea51475f --></div></section></section><section aria-labelledby="managing-injection-site-problems" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-injection-site-problems">How should I manage injection site problems?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 685f8c4d-bc94-4919-a780-03487ee20b0f --><!-- begin field 27822ae9-f960-411d-858f-071ad44c4ae2 --><ul><li><strong>Painful injections</strong><ul><li>Advise the person to numb the area (for example by rubbing with a piece of ice) for 15–20 seconds before injecting.</li><li>Ensure that insulin is not used straight from the refrigerator — cold insulin can make injection painful.</li><li>Ensure that the person uses a new needle for every injection.</li><li>Consider changing the size of the needles — a shorter needle may be less painful.</li><li>Review the person's <a class="topic-reference internal-reference" href="index.html#injection-technique">injection technique</a>.</li></ul></li><li><strong>Bleeding and bruising</strong><ul><li>Reassure the person that bleeding may occasionally occur when the needle is withdrawn.</li><li>Advise them to gently apply pressure to the site for a couple of minutes to minimize bruising.</li><li>Review the <a class="topic-reference internal-reference" href="index.html#injection-technique">injection technique</a> — bruising and bleeding can occur if the insulin is accidentally injected intramuscularly (instead of subcutaneously).</li><li>Consider changing the size of the needle — a shorter needle may reduce the problem of injecting insulin intramuscularly.</li></ul></li><li><strong>Redness, swelling, and itching at the site of injection</strong><ul><li>Reassure the person that local reactions usually resolve after a few days (sometimes several weeks).</li><li>Consider referring the person to the diabetes team for consideration of switching to an insulin analogue if local reactions with human insulin are problematic and persist for longer than 2–4 weeks. </li><li>Exclude other causes for the symptoms, such as a reaction to soap or cosmetics, poor injection technique, or reaction to the preservatives in the insulin preparations (in which case a change of insulin preparation may be needed). Information on each product's excipients (including preservatives) can be found in the manufacturer's Summary of Product Characteristics (see <a href="http://www.medicines.org.uk/" data-hyperlink-id="ed70ae71-aec2-4b3d-b6bd-a93100a81d3c">www.medicines.org.uk</a> for more information).</li></ul></li><li><strong>Lipohypertrophy</strong><ul><li>Explain that lipohypertrophy is caused by repeatedly injecting the same small area, resulting in a build up of lumps under the skin. This can cause erratic absorption of insulin and can be unsightly.</li><li>Offer reassurance that this can be minimized by rotating <a class="topic-reference internal-reference" href="index.html#injection-site">injection sites</a>.</li><li>Advise the person not to inject insulin into affected areas — they should wait until the affected area has become soft before reusing it.</li><li>Explain that depending on the severity of lipohypertrophy, the area may take some time to recover (from weeks to several months or longer). Lipoatrophy (localized loss of fat tissue) can rarely occur with human insulin and insulin analogues.</li></ul></li><li><strong>Insulin leakage</strong><ul><li>Advise the person to leave the needle in the skin for 5–10 seconds (or longer for large doses) to ensure that the entire dose is injected.</li><li>They should <em>not</em> inject a second insulin dose to compensate for the leaked insulin.</li><li>Review the person's <a class="topic-reference internal-reference" href="index.html#injection-technique">injection technique</a> if leakage occurs often, and consider the need for needles of different lengths.</li></ul></li></ul><!-- end field 27822ae9-f960-411d-858f-071ad44c4ae2 --><!-- end item 685f8c4d-bc94-4919-a780-03487ee20b0f --></div><section aria-labelledby="basis-for-recommendation-d15" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-d15">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d1586d83-18b5-4cb0-929f-b7b9b0525b86 --><!-- begin field 310c1570-18f2-4bf9-af09-aeebd0476cd7 --><p>This information is largely taken from the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>] and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016b</a>], the <em>Clinical Practice Consensus Guidelines 2018: insulin treatment in children and adolescents with diabetes</em> published by the International Society for Pediatric and Adolescent Diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Danne, 2018</a>], and information on the Diabetes UK website (<a style="background-color: #ffffff;" href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/insulin" data-hyperlink-id="250bea60-9491-4190-a85f-a93100b5e5ba">www.diabetes.org.uk</a>). Recommendations have also been extrapolated from the Royal College of Nursing guideline <em>Starting injectable treatment in adults with Type 2 diabetes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>].</p><!-- end field 310c1570-18f2-4bf9-af09-aeebd0476cd7 --><!-- end item d1586d83-18b5-4cb0-929f-b7b9b0525b86 --></div></section></section><section aria-labelledby="managing-other-adverse-effects-of-insulin" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-other-adverse-effects-of-insulin">How should I manage other possible adverse effects of insulin therapy?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 32be0316-57cf-4651-818c-20b0becc0f47 --><!-- begin field ad547558-288c-49ef-b504-2b2ba784620f --><p><strong>Other possible adverse effects of insulin therapy include:</strong></p><ul><li><strong>Altered vision (uncommon) </strong>— on initiation of insulin treatment, altered vision may occur if blood glucose levels change markedly.<ul><li>Reassure the person that this is usually temporary.</li><li>Advise the person to avoid changing their glasses until their blood glucose levels have stabilized.</li></ul></li><li><strong>Acute painful neuropathy resulting from rapid improvement of blood glucose control </strong>— rapid improvement in blood glucose control can lead to acute symptomatic neuropathy.<ul><li><div>Reassure the person that this is a self-limiting condition that improves symptomatically over time.</div></li><li><div>Explain that the specific treatments for this condition:</div><ul><li>Aim to make the symptoms tolerable until the condition resolves.</li><li>May not relieve pain immediately and may need to be taken regularly for several weeks to be effective.</li></ul></li><li><div>Advise the use of simple analgesics (paracetamol or a nonsteroidal anti-inflammatory drug [NSAID] if indicated) and local measures (such as a bed cradle [a frame that attaches to the bed to keep sheets and blankets from touching and rubbing the body]) to relieve symptoms. </div><ul><li>If simple analgesics are ineffective, offer treatment as described in the CKS topic on <a class="topic-reference external-reference" href="../../../neuropathic-pain-drug-treatment/index.html">Neuropathic pain - drug treatment</a>. </li><li>Simple analgesia may be continued until the effects of additional treatments have been established.</li><li>The use of weak opioids is not recommended due to the risk of dependency associated with their use.</li></ul></li><li><div>Do not relax diabetes control if this condition is identified.</div></li></ul></li><li><strong>Insulin oedema (rare) </strong>— this occurs mostly in people with poor glucose control and progressive weight loss who are treated with relatively high doses of insulin.<ul><li>Reassure the person that the oedema should resolve within 3–4 days after reduction of the insulin dose. Treatment with a diuretic is not indicated.</li><li>Consider other causes of oedema, for example heart failure. See the CKS topic on <a class="topic-reference external-reference" href="../../../heart-failure-chronic/index.html">Heart failure - chronic</a>.</li></ul></li></ul><!-- end field ad547558-288c-49ef-b504-2b2ba784620f --><!-- end item 32be0316-57cf-4651-818c-20b0becc0f47 --></div><section aria-labelledby="basis-for-recommendation-1ed" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-1ed">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1ed1500e-fa9b-4e85-bf88-0e068fcd03dd --><!-- begin field a93aaaaf-d444-43f1-8ae5-54cb700f9f93 --><h5>Managing altered vision</h5><ul><li>These recommendations have been extrapolated from expert opinion in the Royal College of Nursing (RCN) guideline <em>Starting injectable treatment in adults with Type 2 diabetes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCN, 2019</a>]. In addition, some manufacturers of insulin highlight that refraction anomalies are uncommon and are usually temporary. They are caused by a marked change in glucose control and occur on initiation of insulin therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>].</li></ul><h5>Managing acute painful neuropathy resulting from rapid improvement of blood glucose control</h5><ul><li>These recommendations are based on the expert opinion and experience of the guideline development group (GDG) for the National Institute for Health and Care Excellence (NICE) guideline <em>Type 1 diabetes in adults: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>]. Evidence identified by the GDG did not show any pharmaceutical intervention to be better than the other in the management of this condition [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>].</li></ul><h5>Managing insulin oedema</h5><ul><li>These recommendations are largely based on expert opinion in a reference textbook on adverse drug reactions [<a class="bibliography-reference internal-reference" href="../../references/index.html">Aronson, 2006</a>] and a review article on the skin-related complications of insulin therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Richardson, 2003</a>].<ul><li>Insulin oedema can aggravate pulmonary oedema, heart failure, and hypertension. The mechanism of action is unclear. It may involve a direct effect of insulin on the kidney, causing reduced sodium excretion, sodium reabsorption, and water retention.</li></ul></li></ul><!-- end field a93aaaaf-d444-43f1-8ae5-54cb700f9f93 --><!-- end item 1ed1500e-fa9b-4e85-bf88-0e068fcd03dd --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">What drug interactions are associated with insulin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item baca3ea8-9101-471b-92fc-8ad68bd6c4f4 --><!-- begin field 22b2e8c7-3a2e-4fdb-946e-0998d7884409 --><ul><li><strong>Drugs that can enhance the hypoglycaemic effects of insulin (and hence reduce insulin requirement) include:</strong><ul><li>Alcohol — signs of <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglycaemia</a> may also become less clear following alcohol intake, and delayed hypoglycaemia may occur (which can be hours after alcohol consumption). Advise people on insulin treatment to:<ul><li>Drink alcohol in moderation (no more than 14 units a week for both men and women, with two or more drink-free days in the week).</li><li>Not drink alcohol on an empty stomach (as the alcohol will be absorbed faster).</li><li>Eat a snack that contains carbohydrate (such as a sandwich or crisps) before and after drinking alcohol — extra insulin is not required. </li><li>Measure their blood glucose regularly, and maintain their blood glucose with appropriate carbohydrate intake. </li><li>Always wear some form of <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">diabetes identification</a> as the reduced awareness of hypoglycaemia may be confused with alcohol intoxication.</li></ul></li><li>Anabolic steroids.</li><li>Angiotensin-converting enzyme (ACE) inhibitors.</li><li>Beta-blockers — beta-blockers may also mask the warning signs of <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglycaemia</a> (such as tremor).</li><li>Fibrates.</li><li>Lanreotide and octreotide — octreotide may also increase insulin requirements.</li><li>Monoamine oxidase inhibitors.</li><li>Salicylates.</li><li>Sulphonamides.</li></ul></li><li><strong>Drugs that can antagonize the hypoglycaemic effects of insulin (and hence increase insulin requirements) include:</strong><ul><li>Corticosteroids.</li><li>Danazol.</li><li>Diuretics (loop and thiazides).</li><li>Glucagon.</li><li>Growth hormone.</li><li>Levothyroxine.</li><li>Oral contraceptives.</li><li>Sympathomimetic drugs (such as adrenaline, salbutamol, and terbutaline).</li></ul></li></ul><!-- end field 22b2e8c7-3a2e-4fdb-946e-0998d7884409 --><!-- end item baca3ea8-9101-471b-92fc-8ad68bd6c4f4 --></div><section aria-labelledby="basis-for-recommendation-8f6" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-8f6">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8f67adcb-f8b5-4b57-b32c-616d8f88afd1 --><!-- begin field bc0c0c77-4e2f-4154-ab7c-2dbc0b12db0c --><p>This information is taken from the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>] and the textbook <em>Stockley's drug interactions (pocket companion) </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Preston, 2015</a>]<em>.</em></p><!-- end field bc0c0c77-4e2f-4154-ab7c-2dbc0b12db0c --><!-- end item 8f67adcb-f8b5-4b57-b32c-616d8f88afd1 --></div></section></section><section aria-labelledby="safety-issues" class="ChapterBody-module--wrapper--2HCfk "><h3 id="safety-issues">What safety issues should the person be aware of?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 34c68c5c-6005-46f2-a04f-b7b1dbe33135 --><!-- begin field 10896c5f-e811-46e9-adf2-236901947252 --><ul><li><strong>Advise people on insulin treatment that:</strong><ul><li>They should use devices that have been recommended or prescribed for them by their diabetes specialist.<ul><li>They should not stop or change their prescribed insulin management regimen without seeking the advice of their diabetes specialist.</li><li>They should contact their diabetes specialist if they are invited by a manufacturer to trial a new device, for example via social media.</li></ul></li><li>They should not use insulin syringes and needles to extract insulin directly from pen devices or refill cartridges.<ul><li>Insulin syringes have graduations only suitable for calculating doses of standard 100 units/mL. If insulin extracted from a pen or cartridge is of a higher strength and that is not considered in determining the volume required, it can lead to a significant and potentially fatal overdose.</li><li>If the person is unable to use their pen device as normal, they should contact their diabetes specialist for advice.</li></ul></li><li>They should always carry some form of identification indicating that they have diabetes, such as a MedicAlert® bracelet, necklace, or watch (available from <a href="http://www.medicalert.org.uk/" data-hyperlink-id="b51bd531-0794-480a-8bd3-abe600faa71b">www.medicalert.org.uk</a>) and the Diabetes ID Card (available from <a href="https://www.diabetes.co.uk/diabetic-products/medipal-card.html" data-hyperlink-id="c384f32f-b5a0-45c3-8fd0-abe600faa744">www.diabetes.co.uk</a>). Adults on insulin therapy should also be given a <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">patient information booklet</a> and an <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">Insulin Passport</a>.</li></ul></li><li><strong>Ensure that the person is:</strong><ul><li>Given information about awareness and management of hypoglycaemia. See the sections on <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">Hypoglycaemia</a> for more information.</li><li>Aware of the need to notify the Driver and Vehicle Licensing Agency (DVLA) if they drive. See the section on <a class="topic-reference internal-reference" href="index.html#driving">Driving</a> for more information.</li><li>Given appropriate information on how to manage their diabetes during a period of illness ('Sick-day rules'). See the sections on <a class="topic-reference external-reference" href="../../../diabetes-type-1/management/management-adults/index.html#managing-intercurrent-illness">Sick-day rules - Adults</a> and <a class="topic-reference external-reference" href="../../../diabetes-type-1/management/management-children-young-people/index.html#managing-intercurrent-illness">Sick-day rules - Children and young people</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-1/index.html">Diabetes - type 1</a> for more information.</li></ul></li></ul><!-- end field 10896c5f-e811-46e9-adf2-236901947252 --><!-- end item 34c68c5c-6005-46f2-a04f-b7b1dbe33135 --></div><section aria-labelledby="basis-for-recommendation-fc3" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-fc3">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fc3f746f-28d9-40d8-8e4e-f8eef46697a5 --><!-- begin field 923758bb-a2c4-4efe-a266-363b09dfaa82 --><ul><li>The recommendation on using devices that have been recommended or prescribed by the diabetes specialist is based on a Medical device alert published by the Medicines and Healthcare products Regulatory Agency (MHRA) [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2016</a>].<ul><li>The MHRA advises that if the person is contacted directly by a manufacturer or other organization to try using a different insulin therapy system, they should first discuss this with their diabetes specialist to avoid risk of hyperglycaemia, hypoglycaemia, or diabetic ketoacidosis.</li></ul></li><li>The recommendation on the risk of severe harm and death due to withdrawing insulin from pen devices is based on an NHS Improvement Patient Safety Alert [<a class="bibliography-reference internal-reference" href="../../references/index.html">NHS Improvement, 2016</a>].</li><li>All other recommendations are based on the National Institute for Health and Care Excellence (NICE) Key therapeutic topic on <em>Safer insulin prescribing</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>].</li></ul><!-- end field 923758bb-a2c4-4efe-a266-363b09dfaa82 --><!-- end item fc3f746f-28d9-40d8-8e4e-f8eef46697a5 --></div></section></section><section aria-labelledby="lifestyle-cultural-issues" class="ChapterBody-module--wrapper--2HCfk "><h3 id="lifestyle-cultural-issues">What additional information and advice should I offer a person with type 1 diabetes on lifestyle and cultural issues?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4e85271a-19c9-4fe5-93a3-0b9223da9456 --><!-- begin field ebb4a1ad-c706-4079-adb2-df39f097b412 --><ul><li>Although insulin treatment for people with type 1 diabetes should only be initiated and managed by healthcare professionals with the relevant expertise and training, other primary healthcare professionals may have a supporting role in providing general information on lifestyle and cultural aspects of insulin treatment. </li><li>Provide information and advice on the following:<ul><li><a class="topic-reference internal-reference" href="index.html#driving">Driving</a> whilst on insulin treatment.</li><li><a class="topic-reference internal-reference" href="index.html#fasting-including-ramadan">Fasting, including Ramadan</a>.</li><li><a class="topic-reference internal-reference" href="index.html#shift-work">Shift work</a>.</li><li><a class="topic-reference internal-reference" href="index.html#holidays-travel">Holidays and travel</a>.</li><li><a class="topic-reference internal-reference" href="index.html#insurance">Insurance</a>.</li></ul></li></ul><!-- end field ebb4a1ad-c706-4079-adb2-df39f097b412 --><!-- end item 4e85271a-19c9-4fe5-93a3-0b9223da9456 --></div><section aria-labelledby="lifestyle-advice" class="ChapterBody-module--wrapper--2HCfk "><h4 id="lifestyle-advice">Advice on lifestyle</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 20efd96f-c94f-4c43-8833-47452b264ead --><!-- begin field c4649393-b461-4729-a8bd-1f69749dc16c --><ul><li>See the sections on <a class="topic-reference external-reference" href="../../../diabetes-type-1/management/management-adults/index.html#lifestyle-management">Lifestyle management - adults</a> and <a class="topic-reference external-reference" href="../../../diabetes-type-1/management/management-children-young-people/index.html#lifestyle-management">Lifestyle management - children and young people</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../diabetes-type-1/index.html">Diabetes - type 1</a> for detailed advice on diet, exercise, alcohol intake, and smoking in people with type 1 diabetes.</li></ul><!-- end field c4649393-b461-4729-a8bd-1f69749dc16c --><!-- end item 20efd96f-c94f-4c43-8833-47452b264ead --></div></section><section aria-labelledby="driving" class="ChapterBody-module--wrapper--2HCfk "><h4 id="driving">Advice on driving</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f3cfdbac-b283-4df7-a665-32d374223fd8 --><!-- begin field 0489b73a-7e40-4c6e-a18d-54dfef709e38 --><ul><li><strong>Remind drivers with diabetes of the need to be particularly careful to avoid <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglyacemia</a>. </strong><ul><li>They should:<ul><li>Have a supply of a <a class="topic-reference internal-reference" href="index.html#managing-an-episode-of-hypoglycaemia">fast-acting carbohydrate</a> in the vehicle and avoid driving if their meal is delayed.</li><li>Check their blood glucose level just before they start the journey and then every 2 hours during the journey. If the blood glucose level is low, they should stop the car in a safe place, switch off the engine and move from the driver's seat, eat or drink <a class="topic-reference internal-reference" href="index.html#managing-an-episode-of-hypoglycaemia">something sugary</a>, then wait until 45 minutes after the blood glucose has returned to normal before continuing the journey.</li><li>Take regular meals, snacks, and rest periods on long journeys, and always avoid alcohol.</li><li>Take particular care during changes of insulin regimens, changes of lifestyle, exercise, and travel.</li></ul></li><li>Remind young people of driving age that the optimal <a class="topic-reference internal-reference" href="index.html#target-levels-children-young-people">target blood glucose self-monitoring level</a> when driving is at least 5 mmol/L. </li><li>Advise drivers with diabetes to always carry <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">diabetes identification</a> to show that they have diabetes in case of injury in a road traffic collision.</li></ul></li><li><strong>Advise people with diabetes that it is the responsibility of the driving licence holder or applicant to notify the Driver and Vehicle Licensing Agency (DVLA) of their medical condition. </strong><ul><li>Drivers can be fined up to £1000 if they do not tell the DVLA about a medical condition that affects their driving. They may be prosecuted if they are involved in an accident as a result. Information on how to report the condition is available on the <a href="https://www.gov.uk/diabetes-driving" data-hyperlink-id="029d20b5-6c6c-4ecf-a196-abe6012feacc">DVLA website</a>.</li><li>Once the condition is reported, the DVLA will send out a detailed letter explaining the licensing and driving requirements and responsibilities. </li><li>Information on Group 1 and 2 entitlements are summarized below. Detailed information is available on the <a href="https://www.gov.uk/diabetes-driving" data-hyperlink-id="bd39f988-7200-4f8a-8667-abe6012efb86">DVLA website</a> and the DVLA guide <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/866655/assessing-fitness-to-drive-a-guide-for-medical-professionals.pdf" data-hyperlink-id="2702bfcc-8345-4f37-a273-abe6012dad4a">Assessing fitness to drive – a guide for medical professionals</a>. </li></ul></li></ul><p><strong>For Group 1 entitlement (to drive a car or motorcycle)</strong><strong>:</strong></p><ul><li>The person must satisfy the following criteria to be licensed for 1, 2, or 3 years:<ul><li>Has adequate awareness of hypoglycaemia.<ul><li>If there is <a class="topic-reference internal-reference" href="index.html#impaired-awareness-of-hypoglycaemia">impaired awareness of hypoglycaemia</a>, they must not drive and must notify the DVLA. Driving may resume after a clinical report by a GP or consultant diabetes specialist confirms that adequate hypoglycaemia awareness has been regained.</li></ul></li><li>No more than 1 episode of severe hypoglycaemia while awake in the preceding 12 months and the most recent episode occurred more than 3 months ago.</li><li>Practises appropriate glucose monitoring as follows:<ul><li>Glucose testing no more than 2 hours before the start of the first journey <em>and</em> every 2 hours after driving has started.</li><li>A maximum of 2 hours should pass between the pre-driving glucose test and the first glucose check performed after driving has started.</li><li>Applicants will be asked to sign an undertaking to comply with the directions of the healthcare professionals treating their diabetes and to report any significant change in their condition to the DVLA immediately.</li><li>More frequent self-monitoring may be required with any greater risk of hypoglycaemia (physical activity or altered meal routine).</li></ul></li><li>Must not be regarded as a likely source of danger to the public while driving.</li><li>Meets the visual standards for acuity and visual fields.<ul><li>If the person has visual complications affecting visual acuity or visual field, they may need to stop driving and notify the DVLA. </li></ul></li><li>Under regular review.</li></ul></li><li>If the person has renal complications or limb complications (including peripheral neuropathy), they may need to stop driving and notify the DVLA.</li></ul><p><strong>For Group 2 entitlement (to drive large vehicles like lorries and buses)</strong><strong>:</strong></p><ul><li>The person must satisfy the following criteria for the DVLA to be licensed for 1 year (with annual review as indicated):<ul><li>Has full awareness of hypoglycaemia.<ul><li>If there is <a class="topic-reference internal-reference" href="index.html#impaired-awareness-of-hypoglycaemia">impaired awareness of hypoglycaemia</a>, they must not drive and must notify the DVLA. The licence will be refused or revoked. </li></ul></li><li>No episode of severe hypoglycaemia in the preceding 12 months.</li><li>Practises blood glucose monitoring as follows:<ul><li>Regular blood glucose testing – at least twice daily including on days when not driving <em>and </em>no more than 2 hours before the start of the first journey <em>and</em> every 2 hours after driving has started.</li><li>A maximum of 2 hours should pass between the pre-driving glucose test and the first glucose check performed after driving has started.</li><li>More frequent self-monitoring may be required with any greater risk of hypoglycaemia (physical activity or altered meal routine), in which case a bus or lorry driver may be licensed if they use one or more blood glucose meters with memory functions to ensure 3 months of readings that will be available for assessment.</li></ul></li><li>Must use a blood glucose meter with sufficient memory to store 3 months of readings.</li><li>Demonstrates an understanding of the risks of hypoglycaemia.</li><li>Has no disqualifying complications of diabetes. If the person has:<ul><li>Visual complications affecting visual acuity or visual field, they must not drive and must notify the DVLA. The licence will be refused or revoked.</li><li>Renal complications, they may need to stop driving and notify the DVLA.</li><li>Limb complications, including peripheral neuropathy, they may need to stop driving and notify the DVLA. Limb problems or amputations are of themselves unlikely to prevent driving since they may be assisted by suitable vehicle adaptations. The ability to safely control a vehicle at all times is the essential requirement.</li></ul></li></ul></li></ul><!-- end field 0489b73a-7e40-4c6e-a18d-54dfef709e38 --><!-- end item f3cfdbac-b283-4df7-a665-32d374223fd8 --></div></section><section aria-labelledby="fasting-including-ramadan" class="ChapterBody-module--wrapper--2HCfk "><h4 id="fasting-including-ramadan">Advice on fasting, including Ramadan</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 29934426-4e45-4fe0-b205-b5fbf28b58cd --><!-- begin field ab7f5df3-1771-4816-b14f-215e3492ffb3 --><ul><li><strong>Advise people with type 1 diabetes that they should not fast, especially if their diabetes is poorly controlled.</strong><ul><li>People with type 1 diabetes are usually exempt from requirements to fast.</li><li>Children and young people with type 1 diabetes are strongly advised not to fast owing to the high risk of acute complications, such as <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglycaemia</a> and probably diabetic ketoacidosis (a serious complication of diabetes characterized by hyperglycaemia, metabolic acidosis, and ketonaemia). </li></ul></li><li><strong>If the person is committed to fasting:</strong><ul><li><strong>Ask them to have a medical assessment 1–2 months before the start of the fast</strong><strong> to review their:</strong><ul><li>Overall wellbeing — this includes an assessment of their glucose control, blood pressure, and lipids.</li><li>Diet and medication — this includes any required changes to their insulin regimen during the fasting period. Seek specialist advice or refer if the person is unsure of how to adjust their insulin therapy during the fasting period.</li></ul></li><li><strong>Emphasize the need to:</strong><ul><li>Check blood glucose levels regularly.</li><li>Break the fast immediately if the blood glucose level is less than 3.5 mmol/L.</li><li>Avoid fasting if they are unwell.</li><li>Avoid excessive intake of carbohydrates and sweetened drinks during the fast-breaking meal, as this can lead to uncontrolled post-prandial hyperglycaemia.</li><li>Avoid rigorous exercise or activity (particularly during the few hours before the sunset meal) as this can increase the risk of <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglycaemia</a>. Encourage the person to maintain their usual physical activity (especially during non-fasting periods of the festival).</li></ul></li><li><strong>Advise the person that they should:</strong><ul><li>Eat foods containing complex carbohydrates at the pre-dawn meal (if applicable). To break the fast, simpler carbohydrates are preferred.</li><li>Include fruits, vegetables, lentils, and yoghurt in the pre-dawn and sunset meals.</li><li>Have the pre-dawn meal as late as possible before the start of the daily fast.</li><li>Increase their fluid intake during non-fasting hours.</li></ul></li></ul></li><li><strong>Further information on <a href="http://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/ramadan" data-hyperlink-id="9b3e6652-ced7-4804-a67b-abfb00eed988">Ramadan and diabetes</a> is available on the Diabetes UK website (<a href="http://www.diabetes.org.uk/" data-hyperlink-id="b363df6e-124f-492e-9fdc-a9310097f8db">www.diabetes.org.uk</a>).</strong></li></ul><!-- end field ab7f5df3-1771-4816-b14f-215e3492ffb3 --><!-- end item 29934426-4e45-4fe0-b205-b5fbf28b58cd --></div></section><section aria-labelledby="shift-work" class="ChapterBody-module--wrapper--2HCfk "><h4 id="shift-work">Advice on shift work</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fa80663f-a8fe-4cbf-a33b-bda99a36cbef --><!-- begin field 4addcc65-8ffd-4be2-887c-c5e1bcd63daf --><ul><li><strong>Shift work, particularly night shifts, is associated with poorer control of diabetes.</strong><ul><li>Changes in routine can affect meal times, medication schedules, and sleep pattern, all of which can lead to poorer control of diabetes.</li></ul></li><li><strong>If a person with type 1 diabetes has to work shifts, </strong>ensure that they know how to adjust their insulin treatment.<ul><li>Refer people who are unsure of what to do to their diabetes specialist team.</li><li>Some structured educational programmes provide training on insulin dose adjustment for shift workers. These may be accessed through the diabetes specialist team.</li></ul></li><li><strong>Advise the person to:</strong><ul><li>Bring food and snacks from home.</li><li>Prepare or freeze meals beforehand so that they are ready to eat when they get home.</li><li>Try to eat in line with a regular day.<ul><li>For example, if working an afternoon shift, they should have a healthy, filling lunch before the shift starts rather than in the middle of the shift. If working a night shift, the should try to eat their main meal before the shift starts at a regular time and have a light snack at break time.</li><li>They should ask their diabetes team for help with planning eating around shifts. This could include getting advice on mealtimes and on types of foods that will keep them full for longer.</li></ul></li><li>Keep hydrated – they should keep a bottle of water or sugar-free drink with them and cut down on caffeinated drinks.</li><li>Discuss with their employer if shift work is causing problems with diabetes management. The employer may offer to alter the shift patterns, make shift times more regular, or suggest a different role within the organization.</li></ul></li><li><strong>Further information on shift work and diabetes is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/your-lifestyle-diabetes-and-food-" data-hyperlink-id="60846e58-5c36-4c17-8809-abe70154d688">www.diabetes.org.uk)</a>. </strong></li></ul><!-- end field 4addcc65-8ffd-4be2-887c-c5e1bcd63daf --><!-- end item fa80663f-a8fe-4cbf-a33b-bda99a36cbef --></div></section><section aria-labelledby="holidays-travel" class="ChapterBody-module--wrapper--2HCfk "><h4 id="holidays-travel">Holidays and travel advice</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3072e600-2301-4516-b0a5-2d784c5fc051 --><!-- begin field 949439f5-824d-4250-bc86-5ce1c2608f5a --><ul><li><strong>Offer general advice on travelling,</strong><strong> for example:</strong><ul><li>Carrying <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">diabetes identification</a>.</li><li>Carrying some form of carbohydrate to treat possible episodes of <a class="topic-reference internal-reference" href="index.html#managing-hypoglycaemia">hypoglycaemia</a>.</li><li>Avoiding excessive alcohol intake.</li><li>Obtaining <a class="topic-reference internal-reference" href="index.html#insurance">travel insurance</a>.</li><li>Taking necessary precautions if <a class="topic-reference internal-reference" href="index.html#driving">driving</a>.</li></ul></li><li><strong>Offer advice on insulin management:</strong><ul><li>Advise the person to carry appropriate quantities of insulin and <a class="topic-reference internal-reference" href="index.html#accessories-for-insulin-therapy">accessories</a> in their hand luggage (and a spare set on the person in case their luggage is lost or stolen).</li><li>Give advice on managing insulin regimens, including advice on how to adapt to the time difference if the time zone change is more than 4 hours.<ul><li>If the person requires more flexibility in their insulin regimen (for example if they are a frequent long-distance traveller or plan to cross many different time zones), seek specialist advice or refer the person to their diabetes specialist team.</li></ul></li></ul></li><li><strong>Provide a letter, or advise the person to obtain one from their specialist diabetes team, to address customs and security measures at airports. </strong>The letter can also help if the person needs to replace lost/damaged/stolen medication or seek medical attention abroad. The letter should detail:<ul><li>All prescribed medication.</li><li>All necessary monitoring and dispensing equipment.</li><li>The necessity of carrying medication, insulin, needles, syringes, and other accessories in hand luggage.</li><li>Contact details of the specialist diabetic team in case information or advice are needed during long trips.</li></ul></li><li><strong>Further information on travel and diabetes is available on the Diabetes UK website (<a href="http://www.diabetes.org.uk/Guide-to-diabetes/Life-with-diabetes/Travel" data-hyperlink-id="b363df6e-124f-492e-9fdc-a9310097f8db">www.diabetes.org.uk</a>) and the Fit for Travel website (<a href="http://www.fitfortravel.nhs.uk/advice/general-travel-health-advice/diabetes.aspx" data-hyperlink-id="755d3c1b-bde6-4e9f-8852-a93100c31097">www.fitfortravel.nhs.uk</a>).</strong></li></ul><!-- end field 949439f5-824d-4250-bc86-5ce1c2608f5a --><!-- end item 3072e600-2301-4516-b0a5-2d784c5fc051 --></div></section><section aria-labelledby="insurance" class="ChapterBody-module--wrapper--2HCfk "><h4 id="insurance">Advice on insurance</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 19534f81-997c-4f7e-958f-e81f36c5bd74 --><!-- begin field 36de97f3-1883-4806-93b0-ea785822f03e --><ul><li><strong>Inform the person receiving insulin that:</strong><ul><li><strong>For car insurance, </strong>they must notify their car insurance company (immediately and on renewal) that they are on insulin therapy.</li><li><strong>For insurance or assurance for loans and life cover,</strong> they must declare their diabetes and any treatment they are taking, including insulin. <ul><li>If they had not been diagnosed with diabetes at the time they took out an insurance policy, they do not need to inform their insurance company. Their premiums will not change, even if they need to start insulin.</li></ul></li><li><strong>For travel insurance, </strong>they should check that the policy covers type 1 diabetes, as policies may exclude pre-existing medical conditions.</li></ul></li><li><strong>Further information on insurance and diabetes is available on the Diabetes UK website (<a href="http://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Insurance/" data-hyperlink-id="d5d9ce95-e7f7-4160-bb29-a93100c30fe5">www.diabetes.org.uk</a>) and the Fit for Travel website (<a href="http://www.fitfortravel.nhs.uk/advice/general-travel-health-advice/diabetes.aspx" data-hyperlink-id="755d3c1b-bde6-4e9f-8852-a93100c31097">www.fitfortravel.nhs.uk</a>).</strong></li></ul><!-- end field 36de97f3-1883-4806-93b0-ea785822f03e --><!-- end item 19534f81-997c-4f7e-958f-e81f36c5bd74 --></div></section><section aria-labelledby="basis-for-recommendation-575" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-575">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5758d9f6-4c40-46f9-aafa-45c9c30efdf5 --><!-- begin field e25b282d-5c90-47e3-8387-4f3219ba9c62 --><h5>Driving</h5><ul><li>These recommendations are based on the Driver and Vehicle Licensing Agency (DVLA) guide <em>Assessing fitness to drive – a guide for medical professionals </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">DVLA, 2020</a>].</li></ul><h5>Fasting, including Ramadan</h5><ul><li>These recommendations are based on expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Al-Arouj, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Hui, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Karamat, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ibrahim, 2020</a>], and on information on the Diabetes UK website (<a href="http://www.diabetes.org.uk/" data-hyperlink-id="b363df6e-124f-492e-9fdc-a9310097f8db">www.diabetes.org.uk</a>) and the Department of Health website (<a href="http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_078409" data-hyperlink-id="c453000e-5605-4d60-8c3f-a9310097f98d">www.dh.gov.uk</a>).</li></ul><h5>Shift work</h5><ul><li>These recommendations are largely based on information on the Diabetes UK website (<a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/your-lifestyle-diabetes-and-food-" data-hyperlink-id="60846e58-5c36-4c17-8809-abe70154d688">www.diabetes.org.uk)</a> and the diabetes.co.uk website (<a href="https://www.diabetes.co.uk/" data-hyperlink-id="6acb9e1c-d62d-497a-971c-abfb00efa9fc">www.diabetes.co.uk</a>). </li></ul><h5>Holiday and travel</h5><ul><li>These recommendations are based on information on the Diabetes UK website (<a href="http://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Travel-and-insurance/" data-hyperlink-id="12b85c9f-991e-4394-bcc8-abe70158208e">www.diabetes.org.uk</a>) and the Fit for Travel website (<a href="http://www.fitfortravel.nhs.uk/advice/general-travel-health-advice/diabetes.aspx" data-hyperlink-id="d8501f1d-4efb-4a64-a375-abe70158230d">www.fitfortravel.nhs.uk</a>).</li></ul><h5>Insurance</h5><ul><li>These recommendations are based on information on the Diabetes UK website (<a href="http://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Insurance/" data-hyperlink-id="d5d9ce95-e7f7-4160-bb29-a93100c30fe5">www.diabetes.org.uk</a>) and the Fit for Travel website (<a href="http://www.fitfortravel.nhs.uk/advice/general-travel-health-advice/diabetes.aspx" data-hyperlink-id="755d3c1b-bde6-4e9f-8852-a93100c31097">www.fitfortravel.nhs.uk</a>).</li></ul><!-- end field e25b282d-5c90-47e3-8387-4f3219ba9c62 --><!-- end item 5758d9f6-4c40-46f9-aafa-45c9c30efdf5 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/insulin-therapy-in-type-1-diabetes/management/insulin-therapy-type-1-diabetes/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>